However, the introduction of melanotan 2 nasal sprays offers researchers an additional option for study designs in which injections are unsuitable for reasons including: Test subjects uncomfortable with self-administering injections Fear of needles Injection site pain Poor test subject compliance Although an MT-II nasal spray has not been specifically evaluated in clinical trials, research supports the compatibility of the MT-II peptide with an intranasal format, along with a long track record of delivering peptides and protein intranasally [3]
Overall, this may help more Canadians living with type 2 diabetes achieve better long-term blood sugar management
Anyone who cannot accept that approval, medication choice, dosage, fulfillment timing, pharmacy routing, and results are not guaranteed - WellMedr's own terms state none of these are guaranteed
We don't accept payment for editorial placement
References 1 AguirreP.MenaN.TapiaV.ArredondoM.NezM
Coughlin SR, Mawdsley L, Mugarza JA, et al
